Common sense.
What is his track record?
Not getting a partner for either Bavi or Cotara
Not doing due diligence on the Phase II results of the 2nd line NSCLC study leading PPHM to release erroneous results. That cost the company 1 million from the loan they had to repay back immediately to start, probably a partnership as well as additional years of development time.
Spending lots of money on himself and not on equipment and people for the company.
He was in the right place at the right time being a buddy of Phil Thorpe but he is not now and never has been an independent scientific mind.
He is not qualified to be a director at any Biotech company much less a CEO.
So, I am pretty confident there is no floundering biotech thinking, get that SK in here to straighten things out.